The largest database of trusted experimental protocols

Mda mb 468 breast cancer cell line

Sourced in United States

The MDA-MB-468 breast cancer cell line is a well-established model for breast cancer research. It is a triple-negative breast cancer cell line, meaning it lacks the expression of estrogen receptor, progesterone receptor, and HER2. This cell line is commonly used to study the biology and behavior of this particular subtype of breast cancer.

Automatically generated - may contain errors

3 protocols using mda mb 468 breast cancer cell line

1

Culturing MDA-MB-468 Breast Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
The MDA-MB-468 breast cancer cell line used in this study was originally obtained from the American Type Culture Collection (Manassas, VA, USA) by the Georgetown Lombardi Comprehensive Cancer Center (Washington, DC, USA) [62 (link)]. Cell cultures were routinely maintained in DMEM (Sigma-Aldrich, St. Louis, MO, USA) containing glucose (4500 mg/L), l-glutamine, and sodium pyruvate (110 mg/L) and supplemented with 10% FBS (SAFC Biosciences, Castle Hill, Australia). Cultures were maintained in antibiotic-free growth medium at 37 °C in a humidified incubator with O2 and CO2 levels set at 21% and 5%, respectively. For induction of hypoxia (HPX) in culture, the cells were passaged in DMEM supplemented with 10% FBS and incubated at 37 °C on an InvivO2 400 workstation (Ruskinn Technology Ltd, Bridgend, UK) at 1% O2 and 5% CO2, and the cells were harvested at 48 h.
+ Open protocol
+ Expand
2

Establishment and Culture of Burkitt Lymphoma Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
All human Burkitt lymphoma cell lines were purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ). MDA-MB-468 breast cancer cell line was purchased from American Type Culture Collection (ATCC). BL cell lines were grown in RPMI-1640 medium supplemented with heat-inactivated 10% or 20% (RAMOS) fetal bovine serum (FBS), 100 U/mL penicillin, 100 U/mL streptomycin, and 25 mmol/L HEPES buffer (all from Lonza) at a density of 0.5–2.0 × 106 cells/mL. MDA-MB-468 cell line was cultured in DMEM low glucose medium (Lonza) supplemented with FBS, penicillin, and streptomycin as above. All cells were grown in a humidified atmosphere at 37 °C with 5% CO2.
PHGDH inhibitor NCT-503 (N-(4,6-dimethylpyridin-2-yl)-4-(4-(trifluoromethyl)benzyl) piperazine-1-carbothioamide) and NCT-503 inactive control (N-(4,6-dimethylpyridin-2-yl)-4-(pyridin-4-yl)piperazine-1-carbothioamide), unable to inhibit PHGDH) were purchased from Sigma-Aldrich. Glutaminase inhibitor CB-839 was purchased from MedChemExpress. All compounds were diluted in sterile dimethyl sulfoxide (DMSO) to obtain 10 mM stocks, aliquoted, and stored in 2–8 °C according to manufacturer’s recommendations.
+ Open protocol
+ Expand
3

Antibody-mediated cytotoxicity assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
The MDA-MB-468 breast cancer cell line was obtained from American Type Culture Collection (Manassas, VA) and cultured in RPMI 1640 supplemented with 10% heat inactivated FBS, penicillin / streptomycin and L-glutamate. These cells were incubated on ice for 2hrs with or without clinical-grade cetuximab or rituximab (negative control). After 3 washes in ice cold PBS, antibody-coated cells were fixed with 1% paraformaldehyde at room temperature for 20 minutes. Repeating 3 washes in ice cold PBS, antibody-coated-fixed cells were resuspended in RPMI 1640 supplemented with 10% FBS, penicillin-streptomycin and L-glutamate. Target cells were added to the PBMs at an effector cell-to-target cell ratio of 3:2 and incubated at 37°C for 16h. Cell-free supernatants were collected for subsequent experiments and analyses.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!